Most Prescribed Malaria Medications in Canada and Geographic Efficacy
The most commonly prescribed antimalarial agents in Canada for travelers are atovaquone-proguanil (Malarone), doxycycline, and mefloquine, with geographic efficacy varying based on chloroquine resistance patterns: chloroquine remains effective only in limited areas (Central America north of Panama Canal, parts of the Middle East), while atovaquone-proguanil and artemisinin-based combinations are first-line for chloroquine-resistant regions including sub-Saharan Africa, Southeast Asia, and the Amazon basin.
Primary Antimalarial Agents Used in Canada
First-Line Prophylaxis Options
Atovaquone-proguanil (Malarone) has become a preferred agent for Canadian travelers due to its excellent safety profile and high protective efficacy against chloroquine-resistant P. falciparum 1. This combination demonstrates cure rates exceeding 93% and requires only 1-2 days before travel initiation, continuing daily during exposure and for 7 days post-departure 2.
Doxycycline serves as an alternative for short-term travelers, particularly when mefloquine is contraindicated 3. It requires daily dosing starting 1-2 days before travel and continuing for 4 weeks after leaving malarious areas 3.
Mefloquine remains available but has fallen out of favor due to neuropsychiatric side effects, though it offers the convenience of weekly dosing 3, 4. Canadian guidelines note this agent is still not universally available 2.
Treatment Regimens
Artemisinin-based combination therapies (ACTs) represent the gold standard for treating uncomplicated P. falciparum malaria, specifically:
- Artemether-lumefantrine: 4 tablets twice daily over 3 days (for patients >35 kg), must be taken with fatty meals 2
- Dihydroartemisinin-piperaquine: 3-4 tablets daily for 3 days based on weight, taken in fasting conditions 2
Intravenous artesunate is the definitive treatment for severe malaria, though availability may require contacting CDC quarantine stations 5.
Geographic Efficacy Patterns
Chloroquine-Sensitive Regions (Chloroquine Effective)
- Central America north of Panama Canal (including Mexico)
- Haiti (notably the only Caribbean area with relapsing malaria species) 3
- Parts of the Middle East and Central Asia 6
- Limited areas of Indonesia 6
In these zones, chloroquine at 100 mg daily (or 300 mg weekly) remains effective 3, 7.
Moderate Chloroquine Resistance (Combination Therapy Recommended)
- West Africa - though resistance patterns are evolving 3
- Parts of East Africa where proguanil may retain some efficacy 3
The combination of chloroquine 300 mg weekly plus proguanil 200 mg daily provides enhanced protection 3, 8.
High-Level Multidrug Resistance (ACTs or Atovaquone-Proguanil Required)
- Sub-Saharan Africa (most regions) 3, 6
- Southeast Asia (Thailand, Papua New Guinea, Greater Mekong subregion) 3, 2
- Amazon basin of South America 6
- Oceania 5
These areas require mefloquine, atovaquone-proguanil, or ACTs due to widespread chloroquine and sulfadoxine-pyrimethamine resistance 3, 2.
Critical Geographic Considerations
Proguanil demonstrates variable efficacy: effective in East Africa but ineffective in Thailand, Papua New Guinea, and West Africa due to dihydrofolate reductase inhibitor resistance 3.
Emerging artemisinin resistance in the Greater Mekong subregion raises concerns about ACT efficacy in Southeast Asia, though these remain first-line treatments 2, 9.
Primaquine for relapse prevention applies to most malarious areas worldwide (except Haiti) due to P. vivax and P. ovale presence, requiring 14-day courses after departure 3. However, G6PD testing is mandatory before extended primaquine use, particularly in Asian populations where severe deficiency is common 7.
Common Pitfalls to Avoid
Do not use mefloquine for self-treatment due to high frequency of dizziness and neuropsychiatric effects at therapeutic doses 3.
Avoid Fansidar (sulfadoxine-pyrimethamine) for routine prophylaxis due to severe adverse reactions; reserve only for presumptive self-treatment when professional care is unavailable 3.
Never confuse Fansimef (mefloquine + Fansidar combination) with mefloquine alone - it is not recommended for prophylaxis 3.
Doxycycline causes photosensitivity (19% of users) and vaginal candidiasis (16% of female users), making it less suitable for beach destinations 4.
ACTs require specific administration: artemether-lumefantrine needs fatty meals for absorption, while dihydroartemisinin-piperaquine requires fasting 2.
Adverse Effect Profiles Influencing Choice
Compared to atovaquone-proguanil, mefloquine users experience significantly higher rates of abnormal dreams (14% vs 7%), insomnia (13% vs 3%), anxiety (6% vs 1%), and depressed mood (6% vs 1%) 4.
Compared to doxycycline, mefloquine causes more neuropsychiatric effects (abnormal dreams 31% vs 3%, anxiety 18% vs 1%) but fewer gastrointestinal issues (dyspepsia 4% vs 14%) and no photosensitivity 4.
Atovaquone-proguanil demonstrates the best overall tolerability with discontinuation rates of only 2% versus 6% for mefloquine 4, 1.